Skip to content

EFFECT OF AYURVEDA PARA-SURGICAL PROCEDURE IN HEARING DIFFICULTY

A RANDOMIZED OPEN LABEL CONTROLLED CLINICAL STUDY ON EFFICACY OF VIDDHAKARMA WITH AND WITHOUT KSHEERABALA 101 TAILA NASYA AND ASHWAGANDHA GHRITAPANA IN THE MANAGEMENT OF BADHIRYA WITH SPECIAL REFERENCE TO SENSORINEURAL HEARING LOSS - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/106746
Enrollment
30
Registered
2026-03-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H905- Unspecified sensorineural hearingloss

Interventions

None listed

Sponsors

Dr Kshamitha Jain V
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects aged between 18 - 60 irrespective of gender, occupation, religion and socio-economic status. 2.Subjects presenting with Krichrena Shruthim (difficulty in hearing). 3.Subjects having SNHL (PTA between 26 dB to 64 dB) with or without Tinnitus. 4.Subjects diagnosed with SNHL for a duration of not more than 5 years. 5.Subjects fit for Nasya Karma. 6.Subjects willing to participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Subjects with uncontrolled systemic illness. 2.Subjects with conductive, mixed hearing loss 3.Subjects with severe to profound Sensorineural hearing loss 4.Subjects with external and middle ear disorders 5.Subjects with vestibular ear diseases like vestibular neuritis, BPPV and Meniere s disease 6.Subjects who have undergone chemotherapy 7.Subjects currently using ototoxic medications. 8.Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Significant reduction in the signs and symptoms of Badhirya with special reference to Sensorineural hearing lossTimepoint: Trial period 30 days. Assessment on 0th day, 8th day and 31st day. Follow up on 45th day

Secondary

MeasureTime frame
Generation of in-depth analysed data on the different aspects of the disease. Generation of data on possible adverse drug reactionTimepoint: Trial period 30 days. Assessment on 0th day, 8th day and 31st day. Follow up on 45th day

Countries

India

Contacts

Public ContactDr Geetha Kumari B

Sri Sri College Of Ayurvedic Science And Research Hospital

ayurgeeta@gmail.com9480056218

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026